Allergan turns down Valeant

Share this article:

Allergan's board has told Valeant to take its takeover offer elsewhere. Modern Healthcare reports that Allergan's board said the $54 million offer was too low, with too much shareholder risk.

CEO David Pyott told MH the fallout would have probably included a reduced R&D budget, less advertising and higher prices for Allergan products.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.